Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results.
Vaxcyte (PCVX) shares jumped over 60% as its experimental pneumococcal vaccine successfully met the primary endpoints in a pivotal late-stage trial for adult use. This success positions the biotech to compete with established players like Pfizer and Merck in the multibillion-dollar vaccine market.
Moderna (MRNA) is lower Wednesday morning, down 3.07% to $149.54 at publication. The move comes after a trailing-month 170% surge alongside a recently closed $2.6 billion convertible notes deal as benchmark yields remain elevated.
Merck's Tulisokibart met primary and secondary endpoints
Merck's Tulisokibart meets primary and key secondary endpoints in Phase 3 ATLAS-UC induction-only study for ulcerative colitis